Profile data is unavailable for this security.
About the company
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
- Revenue in ILS (TTM)0.00
- Net income in ILS-10.07m
- Incorporated1968
- Employees9.00
- LocationPurple Biotech Ltd4 Oppenheimer St., Science ParkREHOVOT 7670104IsraelISR
- Phone+972 39333121
- Fax+972 35097196
- Websitehttps://purple-biotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBL Hadasit Bio Holdings Ltd | 0.00 | -2.12m | 4.24m | 16.00 | -- | 6.17 | -- | -- | -0.1911 | -0.1911 | 0.00 | 0.062 | 0.00 | -- | -- | -- | -59.09 | -2.24 | -98.71 | -2.40 | -- | -- | -- | -- | -- | -2.72 | 0.00 | -- | -- | -- | 87.99 | -- | -- | -- |
| Purple Biotech Ltd | 0.00 | -10.07m | 18.67m | 9.00 | -- | 0.1788 | -- | -- | -0.0158 | -0.0158 | 0.00 | 0.0562 | 0.00 | -- | -- | 0.00 | -8.80 | -34.27 | -10.44 | -37.87 | -- | -- | -- | -- | -- | -- | 0.0077 | -- | -- | -- | 63.58 | -- | -- | -- |
| X T L Biopharmaceuticals Ltd | 1.41m | -69.65m | 26.61m | 0.00 | -- | 0.2201 | -- | 18.93 | -0.3163 | -0.3163 | 0.0064 | 0.1278 | 0.0192 | -- | 0.7012 | 42,607.21 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| Merchavia Holdings and Investments Ltd | 455.00k | -16.51m | 38.96m | 90.00 | -- | 1.74 | -- | 85.62 | -0.9269 | -0.9269 | 0.0251 | 1.07 | 0.017 | -- | 2.32 | 5,055.56 | -61.87 | -9.41 | -65.61 | -9.67 | -- | -- | -3,628.57 | -468.97 | -- | -0.1069 | 0.00 | -- | 307.39 | 4.24 | 57.04 | -- | -- | -- |
| BioLine RX Ltd | 39.44m | -9.22m | 39.33m | 28.00 | -- | 0.6502 | -- | 0.9973 | -0.0067 | -0.0067 | 0.0186 | 0.0232 | 0.2752 | 2.19 | 7.05 | 1,408,582.00 | -6.43 | -48.18 | -11.04 | -63.37 | 50.69 | -- | -23.38 | -450.09 | 1.93 | -2.59 | 0.3681 | -- | 502.92 | -- | 84.79 | -- | -5.85 | -- |
| Nextage Therapeutics Ltd | 413.00k | -3.28m | 63.15m | -- | -- | -- | -- | 152.90 | -0.0998 | -0.0998 | 0.0126 | -0.1637 | 0.5704 | -- | 2.76 | -- | -479.28 | -265.82 | -- | -- | 18.40 | 22.53 | -840.19 | -2,390.64 | -- | -110.94 | -- | -- | -52.85 | 6.82 | 15.36 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Purple Biotech Ltd's reporting currency: Israeli Shekel ILS
